

ASIAMEDIC LIMITED
(the "**Company**")
(Incorporated in the Republic of Singapore)
Company Registration No.: 197401556E

RESPONSE TO SGX-ST ON QUERY ON UNSUAL TRADING ACTIVITY

The Board of Directors ("**Board**") of AsiaMedic Limited (the "**Company**") refers to the queries from the Singapore Exchange Securities Trading Limited ("**SGX-ST**") regarding trading activity on 13 January 2017. The Company sets out the SGX-ST's queries and its responses as follows:

Question 1: Are you (the issuer) aware of any information not previously announced concerning you, your subsidiaries or associated companies which, if known, might explain the trading? Such information may include events that are potentially material and price-sensitive, such as discussions and negotiations that may lead to joint ventures, mergers, acquisitions or purchase or sale of a significant asset. You may refer to paragraph 9 in Appendix 7A of the Catalist Rules for further examples. - If yes, the information shall be announced immediately.

Response: As mentioned by the Company in its responses to the SGX-ST's queries regarding its trading activity on 21 September 2016, the Group is actively pursuing potential expansion opportunities with a view to boosting growth and enhancing shareholder value.

The Company has received expressions of interest regarding a potential commercial opportunity and is in discussions with the relevant parties on such opportunity. As at the date hereof, no definitive agreement has been entered into and there is no assurance that any transaction will materialise. The Company will make an announcement if and when a definitive agreement is entered into.

The Company is also reviewing several capital expenditure plans including possible relocation of clinics and upgrading of medical equipment.

Apart from the above, the Company is not aware of any information not previously announced concerning the Company, its subsidiaries or associated companies which, if known, might explain the trading.

In the meantime, shareholders of the Company are advised to exercise caution when dealing in the shares of the Company.

Question 2: Are you aware of any other possible explanation for the trading? Such information may include public circulation of information by rumours or reports.

Response: Save as aforesaid, the Company is not aware of any other possible explanation for the trading.

Question 3: Can you confirm your compliance with the listing rules and, in particular, Catalist Rule 703?

Response: The Company confirms that it is in compliance with the listing rules and, in particular, Catalist Rule 703 regarding the disclosure of material information.

By Order of the Board
Foo Soon Soo
Company Secretary

13 January 2017

*This announcement has been prepared by the Company and its contents have been reviewed by the Company's Sponsor, Xandar Capital Pte Ltd (the "**Sponsor**"), for compliance with the Listing Manual (Section B: Rules of Catalist) of the SGX-ST. The Sponsor has not independently verified the contents of this announcement including the accuracy or completeness of any of the information disclosed or the correctness of any of the statements made, opinions expressed or reports contained in this announcement. This announcement has not been examined or approved by the SGX-ST. The SGX-ST and the Sponsor assume no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made, or reports contained in this announcement.*

The contact person for the Sponsor is Ms Pauline Sim (Registered Professional, Xandar Capital Pte Ltd) at 3 Shenton Way, #24-02 Shenton House, Singapore 068805, telephone number: (65) 6319 4954